Association Of British HealthTech Industries

Suite 2, 4th Floor, 1 Duchess Street, W1W 6AN London
United Kingdom of Great Britain and Northern Ireland
Telephone +44 207 9604376
Fax +44 20 72614360
exhibitions@abhi.org.uk

Contact

Alison Cassells

Lottie McMahon

Paul Benton

Company news

Date

Topic

Download

Nov 19, 2019

The World’s First Vascular Access Air Warming Device Achieves 87.5% Success!

The Airglove warming device works in just 3 minutes gently warming the patients arm to the selected temperature. With extended courses of treatment such as chemotherapy repeated cannulation is often required. Airglove can benefit fragile or hidden veins by gently warming up the arm.  It is so easy to use no more warm water arm immersion, heat pads or warm towels. The nurse/practitioner simply places the patients arm in the double walled polythene glove, selects the temperature and starts the device.  The patient will feel the warm air fill up and circulate around the glove and vent away through the single slit perforation. After 3 minutes Airglove will automatically stop with an alert sound. This proven patient solution provides patient comfort, easier cannulation, saves on time & wasted consumables along with potential gram-negative infections.

Airglove is CE certified with over 5 years of development in conjunction with NHS Innovations and The Maidstone & Tunbridge Wells NHS Trust. In their patient service evaluation Airglove achieved 87.5% 1st time cannulation success in their hardest to cannulate oncology patients. This new innovation we are delighted to announce will soon be available for the US market in June 2020.

More Less

Nov 19, 2019

Medezine Ltd launch innovative Cast Removal Saws and Mortuary Autopsy Saws at MEDICA 2019

Medezine are proud to announce the launch of a NEW & Innovative range of Cast Removal Saws and Mortuary Autopsy Saws. Combining 20years experience with comprehensive market research the new Medezine Saw range encompasses everything Global healthcare demands. Reliability, patient & user safety, quiet, portable and cost effective.

Overview

For over 20 years Medezine has been a market leading manufacturer of high quality medical equipment. The company has experienced record growth and profitability with investment in new products with excellent support and training packages.

Export Partnerships

Medezine successfully export’s Globally partnering with specialist Healthcare Distributors, ensuring commercial advantage. Medezine values professional partners with local knowledge and understanding of their market requirements. Medezine offers comprehensive technical and sales support to all distributors.

To find out more please visit;

Web www.medezine.co.uk

Email sales@medezine.co.uk

Tel +44 (0) 114257 6002

 

 

More Less

Nov 19, 2019

ProtecX & Burlington launch innovative radiation protection garment at MEDICA

ProtecX & Burlington are launching the ‘Princess Vest’, an innovative radiation protection garment designed specifically for women. This new style provides excellent mammary protection, and with 1 in 8 women now predicted to get Breast Cancer, it is imperative that we do everything we can to protect those that are more exposed to the damaging health effects caused by low level radiation. That’s why we’re donating £5 of every vest sold to a non-profit breast cancer charity.

More Less

Nov 18, 2019

De Soutter Medical launch high speed drill at MEDICA 2019

De Soutter Medical are pleased to introduce the new hekaDrill system. Ultra-high speed 85,000 rpm, slimline and lightweight with total precision for Spinal, Neuro and ENT procedures.
Featuring user friendly innovations such as customisable user profiles and wireless foot pedals.
Visit them on the ABHI UK Pavilion, stand 16M17-3 to find out more

More Less

Nov 18, 2019

The first single use mouth prop in the world with an integral tether

Following an extensive research and development programme, Robinson Healthcare is delighted to announce the launch of Instrapac Manta® - the world’s first intraoral mouth prop with a moulded integral tether.

Designer, Dr Ralph Day, was inspired to design a new mouth prop after several years of using alternative products, most of which had inherent design flaws.

He said: “Most mouth props in use are reusable items and are very difficult to decontaminate before re-sterilisation.  The most commonly used mouth prop is manufactured from a rubber compound which develops an unpleasant odour after repeated sterilisation and potentially harbours microorganisms within its surface structure.  These devices are also designed with multiple crevices and chains which are extremely difficult to clean effectively.  I was also very concerned that current product options are neither comfortable for the patient nor clinician friendly.  For all these good reasons, I was determined to develop an innovative product solution”.

The result of several years R&D and clinician consultation is the Instrapac Manta® single use, sterile intraoral mouth prop, a unique product full of innovative clinical design features.

More Less

Nov 18, 2019

Innovative drain disinfectant that kills and prevents biofilms launched at MEDICA 2019

Infection prevention specialist GAMA Healthcare is launching a ground-breaking drain disinfectant at MEDICA 2019 that kills, removes and prevents formation of biofilms, including the highly resistant Gram-negative species.

Featuring foaming peracetic acid generating granules, Clinell Drain Disinfectant takes only 15 minutes to eradicate even the most persistent of biofilms, preventing regrowth for at least 4 days.

Ideal for cleaning and high-level disinfecting of sink and shower drains in augmented care hospital wards, the unique formulation targets throughout the entire drainage system killing bacteria and the slimy build up of biofilm in which germs survive and multiply.

It breaks down stubborn biofilms and destroys 99.9999% of bacteria including hard-to-eradicate pathogens such as Klebsiella, Pseudomonas and Enterobacter.

Whilst ‘traditional’ chlorine-based treatments only kill the bacteria living close to and around the sink outlet – allowing them to regrow quickly – Clinell Drain Disinfectant tackles both the bacteria and the way they thrive, all the way down through the drainage trap.

After an initial usage of three consecutive days, using Clinell Drain Disinfectant twice weekly can help prevent the regrowth of biofilms.  This helps to prevent healthcare-associated infections and potential water-related outbreaks of infection.  The product can be used as part of a hospitals planned preventive maintenance programme to avoid ward closures and costly maintenance and replacement costs.

Dr Teresa Layer, Science and Innovation Director at GAMA Healthcare said: “Working in collaboration with researchers at Cardiff University, GAMA Healthcare is pioneering new and innovative ways to tackle biofilms in healthcare environments. The development of Clinell Drain Disinfectant is the result of two years of collaborative work and we are extremely delighted to be able to launch it on the UK Pavilion at MEDICA this week.”

GAMA Healthcare is a dynamic, innovative company at the forefront of infection prevention technology. The company specialises in the manufacture and distribution of revolutionary infection prevention control products and the provision of exceptional training and aftercare support.

Founded by two medical doctors, GAMA is the preferred choice for infection prevention professionals worldwide. To find out more visit the company on the ABHI UK Pavilion in hall 16, stand 16M 11-1.

More Less

Nov 18, 2019

World’s first digital testing device for early bowel cancer screening showcased at MEDICA 2019

Oxford MEStar – an Oxford University bioengineering spinout company – will be joining the ABHI UK Pavilion at MEDICA 2019 (18 – 21st November 2019) to showcase the world’s first digital Faecal Occult Blood testing devices to enable early bowel cancer identification.

 Originally formed by scientists from the Institute of Biomedical Engineering at Oxford University, measure Bowel Health is the company’s first product in a series of digital handheld diagnostic tests. 

It is the only digital faecal occult blood (FOB) testing device of its kind and uses patented technology originating from research carried out over ten years at the Universities of Glasgow and Oxford, to detect the early signs of bowel conditions including cancer.

The measure bowel health test is sold as a self-testing device, designed to be used in the privacy of one’s own home. As well as showcasing this pioneering device at MEDICA, Oxford MEStar will also be launching a new version of the product, measurePRO, aimed at the professional primary care market.

Bowel (colorectal) cancer is the third most common form of cancer worldwide. In the UK, bowel cancer is the fourth leading form of cancer, and the second most common cause of cancer death. While symptoms do not usually appear until the cancer is advanced, early medical interventions can achieve up to 90% survival – placing a strong emphasis on the need for early diagnosis and screening. Recent research suggests that rates of bowel cancer have been significantly increasing throughout the world, with the greatest increases shown to be in young age groups (<40 year old) mostly excluded from population-wide screening programmes. The availability of novel cost and time effective screening technologies such as measure is key to extending early screening to wider sections of the population.


Oxford MEStar’s Business Development Manager, Dr. Simon Bayly, said: “Our in-vitro diagnostic device works on a patented electrochemical technology, which converts the presence of blood in stool into a measurable electrical signal, increasing the chances of catching bowel cancer early on, when the chances of a positive outcome are highest.

“We are proud of our continued R&D work in developing new products and are excited to be joining the ABHI UK Pavilion this year and launching our new professional testing kit at MEDICA. Bowel cancer causes 16,000 deaths in the UK every year and over half of cases are preventable, so it’s vital to support the work of early diagnosis and treatment.”

Compared to traditional faecal occult blood tests, which utilize either guaiac paper or immunochemical lateral flow tests, Oxford MEStar’s technology makes use of a patented electrochemical technology to analyse the peroxidase activity from blood present in stool samples. The new technology allows the test to be performed in under a minute, and the digital nature of the signal removes all uncertainties linked to test timing and result interpretation. Furthermore, the unique design of the testing minimizes the number of steps required to run the test, making it user-friendly and mess-free, thereby encouraging more people to take the test and increasing test compliance.

The use of a patented electrochemical technology spells a step change in the way bowel cancer has previously been diagnosed, providing an easy-to-use technology for private users and clinicians.

Paul Benton, Managing Director, International at the ABHI added: “We are looking forward to welcoming Oxford MEStar on the ABHI pavilion at MEDICA. Their pioneering product is just one of the many exciting hi-tech solutions for medical technology that will be showcased on the UK pavilion this year.”

MEDICA is taking place from 18 – 21 November 2019 and throughout the show, Oxford MEStar will be located on the ABHI UK Pavilion - hall 16 Stand 16K03-3. or to book an appointment with the Oxford MEStar team at the exhibition please contact: Dr. Simon Bayly (simon.bayly@oxford-mestar.com) and Dr. Robert Wang (robert.wang@oxford-mestar.com).

 For more information visit www.measurebowelhealth.com and www.oxford-mestar.com

More Less

Nov 12, 2019

Surgical Holdings launch Rigid Endoscope Repair Service at MEDICA 2019

An award-winning British manufacturer is delighted to be launching its ‘rigid endoscope repair service’ at MEDICA 2019.

Surgical Holdings offers global hospitals a fast, reliable, cost-effective instrument repair service. The company’s team of highly trained technicians can repair broken rigid endoscopes used in a variety of minimally invasive surgery including laparoscopy, arthroscopy, gynaecology, and urology.

The company replaces broken parts, as well as resetting the endoscopes to OEM specifications and carrying out quality testing. With over 30 years’ experience, they are ISO 13485 accredited to ensure quality is controlled and managed.

Surgical Holdings' rigid endoscope workshop is situated at the company’s head office in Southend-on-Sea, 50 miles from London, and caters for all common brands of endoscope.

The multi-skilled technical team carries out minor lens repairs, objective replacement and full refibre on site, complete with an industry-leading 18-month warranty.

Managing Director of Surgical Holdings, Daniel Coole: “We are delighted to offer our global network of distributors a repair service that enables them to cater for the needs of hospitals around the world. The service is a result of significant investment and success domestically over the last 3 years and we are proud to be able to launch it at MEDICA. We are keen to grow our global export network and are looking for suitable partners during the exhibition.”

Surgical Holdings was established by surgical instrument maker, Philip Coole, 31 years ago; initially manufacturing Surgical Instruments and Orthopaedic Implants.

Over the years the company has diversified into optics at the request of customers, who were keen to see the same high-quality level of workmanship and customer service taken into the world of endoscopes.

If you would like to speak Surgical Holdings about becoming one of their global distributors please visit them on the ABHI UK Pavilion, Stand 16K03-03.

 


 

More Less

Nov 8, 2019

TriMedika – Leaders in Non-contact thermometer

TriMedika designs, develops and manufactures clinical non contact IR thermometers and will be exhibiting at Medica 2019 from 18th – 21st November in Dusseldorf. The TriMedika international sales team will be demonstrating TRITEMP™, the ZERO consumables, ZERO contact thermometer which is in use across NHS (UK) hospital trusts and European hospitals and clinics.

TriMedika’s mission is to put technology into the hands of medical professionals for the benefit of patients and nurses alike, enabling cost savings, optimisation of infection control and most importantly, improved patient outcomes.

TriMedika’s TRITEMP™ uses ZERO consumables, so enables significant cost savings to healthcare organisations by mitigating the need for single use plastic probe covers and reducing the environmental impact of contaminated plastic waste.

The ZERO contact feature of TRITEMP™ has been widely praised by Infection Prevention nurses at the recent RCN Congress, recognising that with 8/10 infectious diseases being spread through contact, TRITEMP™ makes a positive contribution to infection control. Healthcare Acquired Infections (HCAIs) cost the NHS an estimated £1 billion annually*.

Looking ahead at the connected future of medical devices, TriMedika’s connected thermometer  TRITEMP Connect™ is already in development and will enable transfer of patient data to the EMR in real time, saving nurse time, eradicating transcription error, ensuring positive patient identification and improved asset management.

TriMedika is seeking forward thinking, dynamic distributors for TRITEMP™ and its future connected products; if this is of interest, please visit is at stand no. 16K11-1. We look forward to meeting you at Medica 2019.

 TriMedika contact details: Julie Brien jbrien@trimedika.com +44 7736884437

More Less

Nov 8, 2019

Linnodee Diagnostics Ltd - specialising in veterinary diagnostic tests for Leptospirosis

Linnodee Diagnostics Ltd. is dedicated to the design and manufacture of clinical and veterinary diagnostic tests for Leptospirosis. The company was established in 1999 by the late Dr Ernest F Logan OBE. 

Linnodee have 3 main products for the diagnosis of Leptospirosis in humans and for veterinary use (bovine and porcine). We have a fourth product currently in development – a lateral flow format to detect Leptospirosis in human serum. It is hoped that this will be available to market in 2020. 

Our human product is ‘Leptorapide’ – a Rapid Agglutination Test – for the screening and detection of specific  leptospira antibodies in human serum. It is a simple, cost-effective and highly specific and sensitive test which can be used in patients where leptospirosis infection is suspected, allowing for prompt confirmation testing and treatment if required. 

 Our veterinary products are a range of ELISA kits for the detection of leptospirosis in cattle and pigs, with high sensitivity and specificity. Leptospirosis is responsible for considerable economic losses in the dairy, beef and pork industries worldwide as a consequence of abortions, still births, reduced fertility and reduced milk production. It is therefore vital for regular screening to be carried out for disease detection, surveillance and control.

 At MEDICA, we are looking for customers and distributors of our products. Our Distributors play an important role in delivering information about our products and the product themselves into the hands of hospitals, laboratories and end-users worldwide.  We are looking for distributors who operate in a professional manner and can communicate information about our products to customers and clearly communicate with us. We have a history of providing exceptional customer service and expect that our distributors will extend a similar level of customer service and support to their end users who purchase Linnodee products.  

More Less

Nov 4, 2019

Gulf between U.S. and U.K. home oxygen fire safety highlighted at MEDICA 2019

BPR Medical - an international leader in the design and manufacture of medical gas therapy solutions - will be joining the ABHI UK Pavilion at MEDICA 2019 (18 – 21st November 2019) at Hall 16 / K03-3 to discuss its recent report, ‘The prevalence and impact of home oxygen fires in the U.S’.

The analysis, which is the first of its kind, revealed that home oxygen fires claim a life every four days in the U.S., and found the likely annual death toll is higher than previous estimates by the National Fire Protection Association (NFPA). Data from the report confirmed that the minimum death rate from home oxygen fires in the U.S. fares poorly with other parts of the world, notably Japan and the United Kingdom.

The research by BPR Medical examines media reports of home oxygen fires between December 2017 and August 2019. 311 incidents were recorded, resulting in 164 deaths. Most fatalities were oxygen users, however 11 were third parties, including family members or other residents. A firefighter died in an incident in October 2018 when he was hit by shrapnel from an exploding propane tank. 

Previous data from the NFPA has estimated that up to 70 people are killed each year from home oxygen fires*, however it always emphasized that these are ‘likely underestimates’. This new analysis suggests that the actual figure could be twice as high, given that some incidents may not be reported or published online, and that subsequent deaths from injuries may not be reported.


BPR Medical’s analysis of recent incidents also found that 71 serious injuries were reported by the media. Most (63 / 89%) were sustained by oxygen users, and included either burns or smoke inhalation injuries, or both. Emergency Rooms record around 1,200 injuries annually from home oxygen fires*, suggesting most incidents go unrecorded in media reports, the basis for the new study.

The study reveals that:

·        Most oxygen fires (72%) were either caused, or probably caused, by patients smoking while using oxygen therapy.

·        Exploding cylinders are referenced in 33% of reported incidents, presenting a high risk to the emergency services and the public.

·        In 124 incidents (40%), a whole dwelling was destroyed.

Richard Radford, Managing Director, BPR Medical, said, “We’ve always suspected the true scale of the risk from home oxygen fires in the U.S. was higher than previously estimated. This data not only confirms the extent of fatalities among home oxygen users themselves, but also the impact on other people, including neighbours, family members, and the emergency services.

“Guidance on reducing the related problem of surgical oxygen fires was produced by U.S. regulators in 2018, based on clear evidence of the problem. We hope this study will provide valuable data to support the changes required to address what remains a material public health issue in the U.S.”

The risk of death from home oxygen fires is far greater in the U.S. compared with the United Kingdom.  Regulation and mandatory incident reporting in the U.K., along with a culture of cooperation between stakeholders, a strong risk assessment process and the use of low-cost risk control measures, such as smoke alarms and thermal fuses (also known as firebreaks), results in a markedly safer outcome for home oxygen users and third parties.

A similar study in 2018 found only one death as a result of a home oxygen fire was recorded in England from 2013-17. It concluded that for the same oxygen user population, the risk of death in the U.S. is 20 times greater.

Firebreaks are now used in more than 25 countries around the world. They are a requirement in Europe under medical device legislation and are specifically mandated in the U.K. and Germany. Japan is transitioning to full adoption by February 2021. Since March 2018, the Veterans Health Administration (VA) in the U.S. has mandated the use of thermal fuses in every home oxygen patient installation.

A copy or the report and infographic is available at www.firebreaks.info/unitedstates/

More Less

Nov 1, 2019

SEERS Medical launch innovative CLINNOVA Couches at MEDICA 2019

SEERS Medical – the leading UK manufacturer of treatment, examination and rehabilitation furniture – will be joining the ABHI UK Pavilion at MEDICA 2019 (18 – 21 November 2019) to launch their groundbreaking range of examination couches.

The company, who lead the UK market in the design and manufacture of medical examination couches, will mark their 10th anniversary by launching their CLINNOVA couches at the global exhibition held in Dusseldorf.

The CLINNOVA range has been designed with clinical innovation in mind and offers new solutions for patients and clinicians, including increased safe working loads, improved infection control, and new ergonomic, configuration and personalisation features.

One of the most significant benefits of the new range is the new Easy Clean Upholstery alongside a modular frame design that enables a choice of three wheel systems, providing greater versatility to accommodate different clinical environments.

Based in Suffolk, SEERS Medical tailor their couch range to different environments, such as Gynaecology, Ultrasound and Phlebotomy, as well as for Physiotherapy, general examinations and minor treatments.

Meeting the rapidly changing demands of the healthcare market is a key focus for the company, who continue to push the boundaries of being the 'industry standard' for medical couches, globally. This means persistently investing in the latest technologies to improve on product design and functionality to fulfil the needs of customers worldwide.

SEERS Medical’s Owner Simon Rees, said: “As a company, we are constantly investing in new technological advances within changing healthcare applications, using state of the art technology to ensure that SEERS Medical products remain leading edge and high quality.

“We look forward to joining the ABHI UK Pavilion at MEDICA this year, where we will be marking our 10th anniversary by launching our new exciting range of medical couches, providing new solutions to patients and clinicians worldwide.”

Paul Benton, Managing Director, International at the Association of British HealthTech Industries, added: “We are excited that SEERS Medical has chosen to launch their ground-breaking examination couches on the ABHI Pavilion, where they’ll be joined by some of the most exciting UK innovations across the medical world. We look forward to welcoming them this year.”

MEDICA is taking place from 18 – 21 November 2019 and throughout the show, SEERS Medical will be located on the ABHI UK Pavilion - Hall 16 Stand 16M01-01.

For more information visit www.seersmedical.com

About the ABHI
ABHI is the UK’s leading industry association for health technology (HealthTech). ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS and regulators. HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is now the largest employer in the broader Life Sciences sector, employing 121,000 people in 3,500 companies, with a combined turnover of £22.2bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 300 members account for approximately 80% of the sector by value.

 

More Less

Oct 23, 2019

Invest Northern Ireland Partner with ABHI at MEDICA 2019

Invest Northern Ireland is delighted to be hosting a Northern Ireland stand on the ABHI UK Pavilion at MEDICA 2019; the largest healthcare exhibition in the world.

Partnering with the UK’s leading HealthTech trade body, ABHI, Invest Northern Ireland will host a variety of companies at the global medical trade fair, to showcase the countries thriving life and health sciences sector.

Over 250 companies operate in the sector, from niche start-ups to global companies. These companies are focused on creating significant advances in the fields of pharma, diagnostics, personalised medicine, connected health and medical devices, built on regional clinical expertise in the areas of oncology, cardiology and respiratory.  

 The region has a strong reputation for innovation in the health technology sector and today researchers are at the forefront of convergent technology in the areas of health data analytics, machine learning and diagnostics. Global companies in located in Northern Ireland include Armstrong Medical, Philips Healthcare, Stryker, Terumo, Bemis Healthcare, and Randox.

 Grainne McVeigh, Director of Life Sciences from Invest Northern Ireland said: “As the economic development agency for Northern Ireland, our role is to help Northern Ireland companies export their products into global markets, with support of our extensive network of overseas offices, including an office in Düsseldorf. We are delighted to be at MEDICA on the ABHI UK Pavilion to showcase the many innovations Northern Ireland has to offer.”

 
Paul Benton, Managing Director, International, ABHI added:“Northern Ireland is home to a wealth of innovative companies, as well internationally recognised universities, Queen’s University Belfast and Ulster University, both renowned for world-leading research in biomedical sciences. It is an honour to be partnering with them at MEDICA to showcase this expertise on a global stage.”

 MEDICA is taking place from 18 – 21 November 2019 and throughout the show, Invest Northern Ireland will be located on the ABHI UK Pavilion - hall 16 Stand K11-1.

 For more information visit https://www.abhi.org.uk/

About ABHI

ABHI is the UK’s leading industry association for health technology (HealthTech). ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS and regulators. HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is now the largest employer in the broader Life Sciences sector, employing 121,000 people in 3,500 companies, with a combined turnover of £22.2bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 300 members account for approximately 80% of the sector by value.

More Less

Oct 3, 2019

UK DIGITAL HEALTHTECH COMPANIES TO SHOWCASE GROUND-BREAKING TECHNOLOGIES AT MEDICA 2019

The world’s first ‘smart’ peak flow meter that connects to a smartphone and a software platform that turns exercise into video games are two of the cutting-edge technologies that will be showcased alongside a range of pioneering UK digital health innovations at MEDICA 2019.

 This year, the ABHI UK Pavilion – organised by the Association of British HealthTech Industries – will highlight a range of ground-breaking UK digital health technologies, giving an international platform to the digital transformation breathing new life into the medical world.

Exhibitors include MIRA Rehab, whose medical software turns physical and cognitive exercise into video games. Using motion tracking sensors, MIRA (Medical Interactive Recovery Assistant) is designed to make physical therapy easier and more fun for patients while helping clinicians track their patients' progress through means of telerehabilitation. By ‘gamifying’ exercise, the device is helping to change the way physical therapy is delivered, which can be a long and arduous process for those in need of rehabilitation.

Another revolutionary new device being showcased on the ABHI UK pavilion is the world’s first ‘smart’ peak flow meter that connects to a smartphone. Utilising smartphone sensor technology, the device can predict a potential attack up to 7 days in advance, allowing asthma patients to better manage their condition. The smart device, created by Smart Respiratory Products, allows patients to understand their peak flow (the measure of how quickly you can blow air out of your lungs) through a mobile app and is set to aid the 235 million asthma sufferers worldwide.

Paul Benton, Managing Director, International, said: “The medical industry is driven by innovation, and digitalisation has allowed the medical world in Britain to take great strides into the future. We are excited to be able to showcase and give an international platform to these ground-breaking technologies on our UK Pavilion at MEDICA.”

Digital health forms part of one of the fastest growing economic sectors in the world. The UK digital health market was valued at $4 billion in 2017 – and is forecasted to reach $28.3 billion by 2025. Globally, the digital health market is set to exceed $379 billion by 2024.

Digital health will be featured prominently at this year’s MEDICA. ABHI will again be leading the UK’s largest and most visible Pavilion of health technology companies at the show, which takes place from 18 – 21 November 2019.

About ABHI

ABHI is the UK’s leading industry association for health technology (HealthTech). ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium sized enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS and regulators. HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is now the largest employer in the broader Life Sciences sector, employing 127,400 people in 3,860 companies, with a combined turnover of £24bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 300 members account for approximately 80% of the sector by value.

More Less

About us

Company details

ABHI is the UK’s leading industry association for health technology (HealthTech).

ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium sized enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS and regulators. HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is now the largest employer in the broader Life Sciences sector, employing 127,400 people in 3,860 companies, with a combined turnover of £24bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 300 members account for approximately 80% of the sector by value.

More Less

Company data

Number of employees

1-19

Company information as a PDF file